Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Elecoglipron

Stage Phase 3Stale

Sponsor AstraZeneca

Route oral

Class Oral small molecule

Mechanism oral small-molecule GLP-1 receptor agonist

Sources

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07667803

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 4500. Conditions Weight Management. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunc

ClinicalTrials.gov NCT07667803 protocol and results modules

registry, as of 2026-10-01Stale

https://clinicaltrials.gov/study/NCT07775404

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 351. Conditions Obesity; Overweight. The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

ClinicalTrials.gov NCT07775404 protocol and results modules

registry, as of 2026-09-16Stale

https://clinicaltrials.gov/study/NCT07723833

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 152. Conditions Healthy Participants. The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.

ClinicalTrials.gov NCT07723833 protocol and results modules

registry, as of 2026-08-28Stale

https://clinicaltrials.gov/study/NCT07534592

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 48. Conditions Healthy Participants. The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

ClinicalTrials.gov NCT07534592 protocol and results modules

publication, as of 2026-06-18Stale

https://pubmed.ncbi.nlm.nih.gov/42259337/

(VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction, in development for weight management in people living with obesity or o

PMID 42259337

Studies

Embold

Registry NCT07667803

Phase Phase 3

Status Recruiting

Enrollment 4500

Start 2026-06-29

Primary completion 2028-07-31

Study completion 2029-07-30

Catalyst Primary completion. 2028-07-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1 - Dose 1

Regimen once daily

Comparator placebo

Population Weight Management

Arm 2 - Dose 2

Regimen once daily

Comparator placebo

Population Weight Management

Arm 3 - Placebo

Regimen once daily

Population Weight Management

Elecoglipron

Registry NCT07775404

Phase Phase 3

Status Recruiting

Enrollment 351

Start 2026-08-21

Primary completion 2028-04-06

Study completion 2028-04-13

Catalyst Primary completion. 2028-04-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1 - Dose 1

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Arm 2 - Dose 2

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Arm 3 - Placebo

Regimen once daily

Population Obesity; Overweight

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Registry NCT07723833

Phase Phase 1

Status Recruiting

Enrollment 152

Start 2026-07-27

Primary completion 2026-11-18

Study completion 2026-11-18

Catalyst Primary completion. 2026-11-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1-Treatment Sequence A

Population Healthy Participants

Cohort 1 - Treatment Sequence B

Population Healthy Participants

Cohort 2 - Treatment Sequence C

Population Healthy Participants

Cohort 2 - Treatment Sequence D

Population Healthy Participants

Cohort 3 - Treatment Sequence E

Population Healthy Participants

Cohort 3 - Treatment Sequence F

Population Healthy Participants

Cohort 4 - Treatment Sequence G

Population Healthy Participants

Cohort 4 - Treatment Sequence H

Population Healthy Participants

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Registry NCT07534592

Phase Phase 1

Status Active, not recruiting

Enrollment 48

Start 2026-04-16

Primary completion 2026-10-01

Study completion 2026-10-01

Catalyst Primary completion. 2026-10-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Group 1: Period 1

Regimen daily

Population Healthy Participants

Group 1: Period 2

Regimen daily

Population Healthy Participants

Group 1: Period 3

Regimen daily

Population Healthy Participants

Group 1: Period 4

Regimen daily

Population Healthy Participants

Group 1: Period 5

Regimen daily

Population Healthy Participants

Group 1: Period 6

Regimen daily

Population Healthy Participants

Group 2: Period 1

Regimen daily

Population Healthy Participants

Group 2: Period 2

Regimen daily

Population Healthy Participants

Group 2: Period 3

Regimen daily

Population Healthy Participants

Group 2: Period 4

Regimen daily

Population Healthy Participants

Group 2: Period 5

Regimen daily

Population Healthy Participants

Group 2: Period 6

Regimen daily

Population Healthy Participants

Group 2: Period 7

Regimen daily

Population Healthy Participants